Caricamento...
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
OBJECTIVE: Novel treatments such as natalizumab and fingolimod achieve their therapeutic efficacy in multiple sclerosis (MS) by blocking access of subsets of immune cells into the central nervous system, thus creating nonphysiological intrathecal immunity. In contrast, daclizumab, a humanized monocl...
Salvato in:
| Pubblicato in: | Ann Clin Transl Neurol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BlackWell Publishing Ltd
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4435700/ https://ncbi.nlm.nih.gov/pubmed/26000318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.181 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|